MLLT3 and acute myeloid leukemia: To this end, cohorts of MLL-AF9 AML recipient mice were treated with MMF either from days 1 to 14 (“early”) or from days 14 to 28 (“delayed”) after transplantation (Supplementary Fig. 4b).